Add Yahoo as a preferred source to see more of our stories on Google. A new treatment for advanced bladder cancer which doubles survival time has been approved for NHS use. The treatment for advanced ...
Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting ...
GlobalData on MSN
J&J reports positive data for Erda-iDRS in bladder cancer
Erda-iDRS delivers erdafitinib into the bladder over three months, enabling localised therapy and reducing systemic exposure.
Researchers at Fondazione Policlinico Universitario Agostino Gemelli IRCCS have developed a promising machine learning algorithm capable of predicting survival and cause of death for patients with ...
A retrospective cohort study suggested that people with color blindness may have a higher risk of mortality from bladder cancer compared with those who can see colors. The researchers hypothesized ...
The phase 2, single-arm INDIBLADE trial assessed induction ipilimumab plus nivolumab followed by CRT in patients with MIBC.
As a potential biomarker of treatment response, ctDNA and utDNA analyses were performed before systemic therapy, at restaging, and for responders at the beginning of adjuvant nivolumab. ctDNA was ...
SurvivorNet on MSN
A breakthrough for muscle-invasive bladder cancer: Padcev plus Keytruda drug combo could transform treatment around surgery
Nearly 200,000 Americans are living with muscle-invasive bladder cancer (MIBC)—and after decades with few major advances, newly presented data may signal a turning point in how the disease is treated.
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...
ONE in 10 A&E patients who complain of a common bladder cancer symptom die within just three months, concerning research suggests. Bladder cancer is one of the most common cancers in ...
Please provide your email address to receive an email when new articles are posted on . Neoadjuvant and adjuvant pembrolizumab plus enfortumab vedotin significantly benefited patients with ...
Non-muscle invasive bladder cancer is cancer that’s only in the inner lining of your bladder. It hasn’t grown into the muscle wall. Your doctor may also call it superficial bladder cancer, urothelial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results